News

Article

First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC

Author(s):

Fact checked by:

Key Takeaways

  • Amivantamab-vmjw and lazertinib combination significantly improves overall survival in EGFR-mutated NSCLC compared to osimertinib alone.
  • The safety profile of the combination is consistent with individual agents, with manageable venous thromboembolic events.
SHOW MORE

The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.

NSCLC | Image Credit: © Axel Kock   – stock.adobe.com

NSCLC | Image Credit: © Axel Kock

– stock.adobe.com

The European Commission (EC) has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of adult patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations.1

The regulatory decision was supported by data from the phase 3 MARIPOSA trial (NCT04487080), which showed that at a median follow-up of 22.0 months, patients treated with amivantamab plus lazertinib (n = 429) experienced a median progression-free survival (PFS) of 23.7 vs 16.6 months for those given osimertinib alone (n = 429; HR, 0.70; 95% CI, 0.58-0.85; P < .001).2,3

Updated findings presented at the 2024 IASLC World Conference on Lung Cancer showed that, at a median follow-up of 31.1 months, a favorable overall survival (OS) trend was observed for the combination vs osimertinib alone (HR, 0.77; 95% CI, 0.61-0.96; P = .019).3 Previously, in January 2025, Johnson & Johnson announced that clinically meaningful and statistically significant improvement in OS was observed for the combination vs osimertinib with a median OS improvement expected to exceed 1 year.4

“This chemotherapy-free regimen has already demonstrated significant PFS improvements, and new topline data suggests it is expected to extend life by a median of 1 year or more in patients with untreated EGFR-mutated NSCLC vs the current standard of care, osimertinib,” Antonio Passaro, MD, PhD, medical oncologist of the Division of Thoracic Oncology at the European Institute of Oncology in Milan, Italy, stated in a news release.1 “These results mark a significant step forward in the treatment of EGFR-mutated NSCLC. Extending life expectancy is a critical indicator of a treatment’s impact. The MARIPOSA study reaffirms the potential of first-line treatment with this combination therapy to redefine the standard of care and offer clinically meaningful improvements in outcomes for patients.”

In August 2024, the FDA approved amivantamab in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.5 This approval was also supported by data from MARIPOSA.

The MARIPOSA trial included patients with locally advanced or metastatic NSCLC who had not received prior treatment in the advanced setting.3 A documented EGFR exon 19 deletion or exon 21 L858R substitution mutation was required for enrollment. Patients also needed to have an ECOG performance status of 0 or 1.

Patients (n = 1074) were randomly assigned 2:2:1 to receive open-label amivantamab plus lazertinib (n = 429); blinded osimertinib alone (n = 429); or blinded lazertinib alone (n = 216). Stratification factors included EGFR mutation type (exon 19 deletion vs exon 21 L858R substitution mutation), race (Asian vs other), and history of brain metastases (yes vs no).

Blinded independent central review–assessed PFS per RECIST 1.1 criteria for amivantamab plus lazertinib vs osimertinib served as the trial’s primary end point. Secondary end points included intracranial PFS, duration of response, and overall response rate; time to treatment discontinuation; time to subsequent therapy; time to second progression; and OS.

Safety data from MARIPOSA showed that the most common any-grade treatment-emergent adverse effects (TEAEs) with the combination included paronychia (68%), infusion-related reactions (63%), and rash (62%).1 The most frequent grade 3 or higher TEAEs consisted of rash (15%), paronychia (11%), dermatitis acneiform (8%) and pulmonary embolism (8%).

Patients treated with amivantamab plus lazertinib experienced higher rates of EGFR- and MET-related AEs and venous thromboembolism; however, rates of diarrhea were higher for osimertinib. Treatment-related AEs led to the discontinuation of all study treatment in 10% of patients in the combination arm. Interstitial lung disease/pneumonitis occurred in 3% of patients in both the combination and osimertinib arms.

References

  1. European Commission approves Lazcluze (lazertinib) in combination with Rybrevant (amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer. News release. Johnson & Johnson. January 21, 2025. Accessed January 21, 2025. https://www.jnj.com/media-center/press-releases/european-commission-approves-lazcluze-lazertinib-in-combination-with-rybrevant-amivantamab-for-the-first-line-treatment-of-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer
  2. Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498. doi:10.1056/NEJMoa2403614
  3. Gadgeel S, Cho BC, Lu S, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: longer follow-up of the MARIPOSA study. Presented at: 2024 IASLC World Conference on Lung Cancer; September 7-10, 2024; San Diego, CA. Abstract OA02.03.
  4. Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib. News release. Johnson & Johnson. January 7, 2025. Accessed January 21, 2025. https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-shows-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-versus-osimertinib
  5. FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer. FDA. August 19, 2024. Accessed January 21, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer
Related Videos
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
Alexander I. Spira MD, PhD, FACP, FASCO
Hidehito Horinouchi, MD, PhD